Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TRAV40 encodes a variable region segment of the alpha chain of the T cell receptor (TCR), an essential component of adaptive immunity[1]. The TCR is a heterodimeric protein complex expressed on T lymphocytes' surfaces, responsible for recognizing peptides presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells[2][7]. During T cell development in the thymus, the alpha chain is produced via somatic recombination of variable (V) and joining (J) gene segments, with TRAV40 being one of many possible V segments available[1][3]. The resulting diversity in TCR specificity enables the immune system to recognize a vast array of pathogens and transformed cells[4][7]. While the TCR complex is vital for T cell activation and is the focus of some immunotherapies, individual V gene segments such as TRAV40 are not direct therapeutic targets, but their use can be monitored in immune repertoire analyses to study immune diversity or clonality in disease[1][3][7].
N/A for TRAV40 specifically (drugs do not target this variable segment directly)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha variable 40 (TRAV40).